BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16044453)

  • 1. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
    Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
    Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
    Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
    Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
    Huh HJ; Huh JW; Yoo ES; Seong CM; Lee M; Hong KS; Chung WS
    Am J Hematol; 2005 Aug; 79(4):267-73. PubMed ID: 16044449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of PRAME gene in acute leukemia and its clinical significance].
    Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
    Zhou PY; Li WJ; Wei CX; Zhou Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1177-81. PubMed ID: 18088461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantification of the PRAME transcripts in patients with acute myeloid leukemia].
    Zhu ZH; Qian J; Lin J; Yao DM; Qian Z; Wang YL; Chen Q; Han LX; Xiao G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):149-52. PubMed ID: 20376794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
    Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
    Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
    Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
    Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
    Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
    Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
    Weisser M; Haferlach C; Haferlach T; Schnittger S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.